HTRA2 and ovarian carcinoma: Furthermore, ovarian cancer cells with higher levels of HtrA2 are more sensitive to cisplatin, and the knockdown of HTRA2 in these cells drastically increases cisplatin resistance and increases cell invasiveness [101].